Sugi Predict

Sugi Predict / Targets / GRM6

GRM6

Metabotropic glutamate receptor 6 · O15303 · GRM6 on Sugi Atlas →

25,978 patent compounds predicted against GRM6, 16,307 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL56509 SCHEMBL56509 0.53 12/20
Eglumetad Eglumetad (SCHEMBL231157) 1.00 11/20
SCHEMBL346142 SCHEMBL346142 0.83 11/20
SCHEMBL56829 SCHEMBL56829 0.53 9/20
SCHEMBL346141 SCHEMBL346141 0.59 8/20
SCHEMBL56830 SCHEMBL56830 0.56 8/20
SCHEMBL346140 SCHEMBL346140 0.52 8/20
SCHEMBL371435 SCHEMBL371435 0.81 7/20
SCHEMBL179722 SCHEMBL179722 0.47 6/20
SCHEMBL56510 SCHEMBL56510 0.60 5/20
SCHEMBL353510 SCHEMBL353510 0.43 5/20
SCHEMBL346473 SCHEMBL346473 0.50 4/20
SCHEMBL346474 SCHEMBL346474 0.50 4/20
SCHEMBL160783 SCHEMBL160783 0.54 3/20
SCHEMBL38175 SCHEMBL38175 0.53 3/20
SCHEMBL108202 SCHEMBL108202 0.53 3/20
SCHEMBL56062 SCHEMBL56062 0.52 3/20
SCHEMBL286993 SCHEMBL286993 0.50 3/20
SCHEMBL286995 SCHEMBL286995 0.50 3/20
SCHEMBL346779 SCHEMBL346779 0.45 3/20

Clinical trials — most relevant to GRM6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders PHASE3RECRUITING
Memantine for Refractory OCD Patients PHASE3UNKNOWN
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial PHASE2/PHASE3NOT_YET_RECRUITING
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK) PHASE2/PHASE3RECRUITING
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation PHASE3COMPLETED
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder PHASE2COMPLETED
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia PHASE2COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia PHASE2UNKNOWN
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders PHASE2COMPLETED
TRPM8 Activators for Peripheral Neuropathy PHASE2ACTIVE_NOT_RECRUITING
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203 PHASE1COMPLETED
Antidepressant Effects of NR2B in Major Depression PHASE1COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial PHASE1COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia PHASE1COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response PHASE1RECRUITING
D-aspartate and Therapeutic Exercise EARLY_PHASE1UNKNOWN
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine EARLY_PHASE1COMPLETED
Changes in Glutamatergic Neurotransmission of Severe TBI Patients EARLY_PHASE1SUSPENDED
Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder EARLY_PHASE1ACTIVE_NOT_RECRUITING
Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN EARLY_PHASE1COMPLETED
Acamprosate: Genes Associated With Response nanCOMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease nanCOMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX nanCOMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy nanUNKNOWN
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Metabotropic Receptors For Glutamate Type 3 In Parkinson's nanUNKNOWN
Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients nanCOMPLETED
Pulsed Electro Magnetic Fields (PEMF) in Depression nanCOMPLETED
The Neuroprotective Effect of Dexmedetomidine Preserving Brain Functional Connectivity in Elderly Patients nanCOMPLETED
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a GRM6 binder may also engage these)

ProteinNameSimilarity
P35349 — 1.000 P35349 →
Q5NCH9 — 1.000 Q5NCH9 →
Q863I4 — 1.000 Q863I4 →
Q68EF4 — 0.979 Q68EF4 →
GRM4 Metabotropic glutamate receptor 4 0.976 landscape →
Q1ZZH0 — 0.975 Q1ZZH0 →
P31423 — 0.974 P31423 →
Q03391 — 0.956 Q03391 →
Q62645 — 0.955 Q62645 →
GRIN2D Glutamate receptor ionotropic, NMDA 2D 0.953 landscape →
Q8VHN2 — 0.950 Q8VHN2 →
Q91ZU9 — 0.947 Q91ZU9 →
GRIN3B Glutamate receptor ionotropic, NMDA 3B (GluN3 0.945 landscape →
Q96BD0 — 0.943 Q96BD0 →
GRIN2C Glutamate receptor ionotropic, NMDA 2C 0.938 landscape →
Q00961 — 0.937 Q00961 →
TRPM5 Transient receptor potential cation channel subfamily M member 5 0.936 landscape →
Q9JLB5 — 0.934 Q9JLB5 →
Q9EQD0 — 0.934 Q9EQD0 →
O97583 — 0.933 O97583 →
GRM8 Metabotropic glutamate receptor 8 0.933 landscape →
Q32KI9 — 0.932 Q32KI9 →
Q61088 — 0.932 Q61088 →
CHRNA10 Neuronal acetylcholine receptor subunit alpha-10 0.932 landscape →
Q5RDQ8 — 0.931 Q5RDQ8 →
Q9R1M7 — 0.931 Q9R1M7 →
Q99N01 — 0.931 Q99N01 →
Q8CHL0 — 0.931 Q8CHL0 →
Q9ULV1 — 0.931 Q9ULV1 →
Q13467 — 0.931 Q13467 →